Prospective Observational Study on the Predictive Value of Cardiac Damage Markers High-sensitivity Cardiac Troponin I (Hs-cTnI), N-terminal Pro-B-natriuretic Peptide (NT-proBNP) and Soluble Suppression of Tumorigenesis-2 (sST2) for Mortality and the Development of Cardiovascular Events in Patients With Type 2 Diabetes (Diabetes-CV).
Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY
The Diabetes-CV study is an observational study designed to assess the prognostic value of serum cardiac damage markers high-sensitivity cardiac troponin I (hs-cTnI), N-terminal pro-B-natriuretic peptide (NT-proBNP), and soluble suppression of tumorigenesis-2 (sST2) in predicting mortality, major adverse cardiovascular events, and diabetic complications in patients with type 2 diabetes.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 50
View:
• type 2 diabetes
• patients attending the outpatient services
Locations
Other Locations
Italy
IRCCS INRCA Hospital
RECRUITING
Ancona
Contact Information
Primary
Anna Rita Bonfigli, PhD
a.bonfigli@inrca.it
0718003719
Time Frame
Start Date: 2024-04-18
Estimated Completion Date: 2028-12-31
Participants
Target number of participants: 1002
Treatments
Subjects with diabetes
Patients with type 2 diabetes attending routine check-ups at the Diabetology Unit outpatient clinic.
Related Therapeutic Areas
Sponsors
Leads: Istituto Nazionale di Ricovero e Cura per Anziani